Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 2/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818649 | 1.00 | GAA (0.56) | GAACA1CA2CA12CA3 | |
| Potassium SCHEMBL367653 | 0.98 | GAA (0.54) | GAACA1CA2CA12CA3 | |
| Propane SCHEMBL3021103 | 0.93 | GAA (0.50) | GAACA1CA2CA12CA3 | |
| SCHEMBL3016245 | 0.89 | GAA (0.46) | GAACA1CA2CA12CA3 | |
| Thiocyanic Acid SCHEMBL8512493 | 0.86 | GAA (0.43) | GAACA1CA2CA12CA3 | |
| Chlorobenzene SCHEMBL3023979 | 0.86 | ALDH1A1 (0.47) | GAACA1CA2CA12CA9 | |
| Benzenethiol SCHEMBL8487581 | 0.84 | CA12 (0.43) | GAACA1CA2CA12CA3 | |
| SCHEMBL7949872 | 0.84 | CYP2C19 (0.42) | GAACA1CA2CA12CA3 | |
| Thiosulfuric Acid SCHEMBL28402065 | 0.83 | GAA (0.54) | GAACA1CA2CA12CA3 | |
| SCHEMBL34 | 0.79 | GAA (0.62) | GAACA1CA2CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 889 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746875-A2 | CARCINOGENESIS REDUCTION WITH PENTAAZA MACROCYCLIC RING COMPLEX | Galera Labs, LLC (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260137817-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS LLC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260092079-A1 | MANUFACTURE METHOD FOR AQUEOUS FORMULATION OF MANGANESE-CONTAINING COORDINATION COMPLEX, FORMULATION, AND METHOD OF TREATMENT | GALERA LABS LLC (US) | 2026-04-02 | — | — | US | claimed |
| US-20250387406-A1 | THERAPY FOR REDUCED OTOTOXICITY FROM CHEMOTHERAPEUTIC AGENT WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS LLC (US) | 2025-12-25 | — | — | US | claimed |
| US-20250109158-A1 | METHOD OF MANUFACTURE OF PENTAAZA MACROCYCLIC RING COMPLEX, INTERMEDIATES, AND PRODUCTS THEREOF | BIOSSIL INC. (CA) | 2025-04-03 | — | — | US | claimed |
| WO-2025024390-A2 | CARCINOGENESIS REDUCTION WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS, LLC (US) | 2025-01-30 | — | — | WO | claimed |
| US-20240299554-A1 | PRODRUGS WITH 1-(DISULFANYL)ALKYLOXY-CARBONYL UNITS | PHARMACYTICS B.V. (NL) | 2024-09-12 | — | — | US | claimed |
| EP-4359419-A1 | PRODRUGS WITH 1-(DISULFANYL)ALKYLOXY-CARBONYL UNITS | Pharmacytics B.V. (NL) | 2024-05-01 | — | — | EP | claimed |
| WO-2024026273-A1 | THERAPY FOR REDUCED OTOTOXICITY FROM CHEMOTHERAPEUTIC AGENT WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS, LLC (US) | 2024-02-01 | — | — | WO | claimed |
| CN-115850140-B | P- (dimethyl sulfonium) benzenesulfonic acid inner salt and preparation method and application thereof | 浙江工业大学 | 2023-12-05 | — | — | CN | claimed |
| US-5399479-A | A thisulfonic acid, a sulfinic acid and an alkynylamino-substi tuted benzoxazole or benzothiazole | EASTMAN KODAK COMPANY (US) | 1995-03-21 | — | — | US | claimed |
| EP-0378831-B1 | Photographic silver halide emulsion | DU PONT DEUTSCHLAND (DE) | 1994-09-07 | — | — | EP | claimed |
| US-5266442-A | Method for increasing the contrast of photographic silver images | AGFA-GEVAERT N.V. (BE) | 1993-11-30 | — | — | US | claimed |
| EP-0495253-A1 | Method for the photographic production of silver images | AGFA-GEVAERT N.V. (BE) | 1992-07-22 | — | — | EP | claimed |
| EP-0378831-A1 | Photographic silver halide emulsion | DU PONT DE NEMOURS (DEUTSCHLAND) GMBH (DE) | 1990-07-25 | — | — | EP | claimed |
| EP-0122125-B1 | SILVER HALIDE EMULSION | KONICA CORPORATION (JP) | 1987-07-15 | — | — | EP | claimed |
| EP-0183673-A1 | Thiosulfonate derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1986-06-04 | — | — | EP | claimed |
| EP-0182768-A1 | Pharmaceutical and veterinary compositions containing thiosulfonate derivatives | SANOFI (FR) | 1986-05-28 | — | — | EP | claimed |
| EP-0122125-A1 | Silver halide emulsion | KONICA CORPORATION (JP) | 1984-10-17 | — | — | EP | claimed |
| US-3977880-A | Direct-positive emulsion containing silver halide grains internally doped with metal ions, surface ripened with gold and sulfur compound and fogged by light exposure | FUJI PHOTO FILM CO., LTD. (JA) | 1976-08-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109158-A1 | METHOD OF MANUFACTURE OF PENTAAZA MACROCYCLIC RING COMPLEX, INTERMEDIATES, AND PRODUCTS THEREOF | PAICS, AADAC, RPS14 | GAA 1859/4885CA1 238/4885CA2 1364/4885 |
| US-20240299554-A1 | PRODRUGS WITH 1-(DISULFANYL)ALKYLOXY-CARBONYL UNITS | SI, SULT1E1, SULT1A1 | GAA 1651/4885CA1 140/4885CA2 110/4885 |
| US-20260092079-A1 | MANUFACTURE METHOD FOR AQUEOUS FORMULATION OF MANGANESE-CONTAINING COORDINATION COMPLEX, FORMULATION, AND METHOD OF TREATMENT | SLC39A11, RPS14, SCN11A | GAA 4076/4885CA1 231/4885CA2 338/4885 |
| US-20260137817-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | CD274, PDCD1, PDCD1LG2 | GAA 4628/4885CA1 339/4885CA2 814/4885 |
| US-20250387406-A1 | THERAPY FOR REDUCED OTOTOXICITY FROM CHEMOTHERAPEUTIC AGENT WITH PENTAAZA MACROCYCLIC RING COMPLEX | SLC39A11, FOLR1, RPS14 | GAA 4760/4885CA1 161/4885CA2 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.